Armis Biopharma's mission is to decrease the quantity and severity of infections that cause human and animal suffering and death through novel, targeted, antimicrobial therapies.
The company’s technology, Veriox®, is a first-of-its-kind, proprietary peracid/hydrogen peroxide based non-systemic, non-resistant antimicrobial agent. Veriox® features a novel Mechanism of Action (M of A) that reduces the likelihood of contributing to resistance against Gram+, Gram-, viral, fungal and chemical/biological warfare pathogens.
Armis is focused on efficacious, non-systemic, non-resistant antimicrobials that work as monotherapies and/or may increase the efficacy of existing systemic antibiotics.
